Amalgamated Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Amalgamated Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$123K	Buy	+17,187	New	+$183K	﹤0.01%	2077

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMS

Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

DOFI

DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amalgamated Financial's RXRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2022: 17,187 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #2077 among its holdings.

128 funds tracked by Wall St. Rank hold RXRX as of Q1 2022.

Amalgamated Financial held 17,187 shares of Recursion Pharmaceuticals worth $123K as of Q1 2022.
Recursion Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Recursion Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2077 holding.
128 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.